182 results on '"Zhu, A.X."'
Search Results
52. Change in Platelet Count and Normal Liver Dosimetry in Patients Receiving Proton Radiation Therapy for Unresectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
53. Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
54. Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study
55. A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
56. Treatment-Induced Changes in Circulating Lymphocyte Populations Associate With Survival of Patients With Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) Treated With Hypofractionated Proton Therapy (HPT)
57. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
58. Evaluation of three satellite precipitation products TRMM 3B42, CMORPH, and PERSIANN over a subtropical watershed in China
59. Influence of Body Mass Index (BMI) on Colorectal Cancer Mutation Status
60. Clinical and Molecular Predictors of Local Failure After SBRT for Liver Metastases: A Secondary Analysis of a Prospective Phase II Trial
61. A Single Arm Phase 2 Study of Individualized Proton-Based Stereotactic Body Radiation Therapy (P-SBRT) of Liver Metastases
62. Early Response Assessment After Hypofractionated Proton Radiation Therapy for Primary Liver Tumors
63. Outcomes After Liver Directed Radiation Therapy for Hepatocellular Carcinoma With Tumor Venous Thrombosis
64. Interfractional and Immobilization Related Respiratory Motion Variability for Treatment of Liver Tumors
65. LBA28 - Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
66. 782TiP - Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150
67. 776TiP - Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
68. 622PD - Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)
69. 377TiP - Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
70. P0288 : CXCR4 inhibition reverts immunosuppressive tumor microenvironment and facilitates Anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma
71. 1592P - Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
72. 775TiP - KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
73. Tolerability of Liver Re-irradiation With Stereotactic Radiation Therapy
74. Impact of Intravenous Contrast Enhancement Phase on Target Definition for Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (IHC): Observations From Patients Enrolled on a Prospective Phase 2 Trial
75. Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study
76. P93 HYPOXIA UNDER SORAFENIB TREATMENT UPREGULATES SDF1a/CXCR4 RESULTING IN MYOFIBROBLAST ACTIVATION, GR1+ CELL INFILTRATION, AND DESMOPLASIA IN HEPATOCELLULAR CARCINOMA
77. 713TiP - Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study
78. 710TiP - A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
79. 698P - Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
80. 617PD - Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
81. Mutational Profile of Gastroesophageal Cancer Compared to Gastric and Esophageal Cancers
82. THU-16 Systemic therapies for cholangiocarcinoma: State of the art 2013
83. Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)
84. Patient Tolerability and Acute Toxicity of Intensity Modulated Radiation Therapy for Treatment of Carcinomas of the Biliary Tract
85. Pilot of Respiratory Gated Proton Beam Therapy for Liver Tumors
86. Abstract No. 347: Chemoembolization with Doxorubicin-Eluting Microspheres for Inoperable Hepatocellular Cancer: Initial Results
87. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer
88. CMR 2005: 7.06: Role of perfusion CT in monitoring anti-angiogenic response in patients with advanced hepatocellular carcinoma
89. Comparison of automatic and patient-activated arrhythmia recordings by implantable loop recorders in the evaluation of syncope
90. LBA16 - Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study
91. Molecular Cloning of Two Small GTP-Binding Proteins from Human Skeletal Muscle
92. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma
93. Soil Mapping Using GIS, Expert Knowledge, and Fuzzy Logic.
94. Representing continuous spatial variation of geographic phenomena using fuzzy logic
95. Representing continuous spatial variation of geographic phenomena using fuzzy logic.
96. Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
97. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
98. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
99. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2
100. O-027 - Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.